Zomedica Corp. (ZOM): Price and Financial Metrics

Zomedica Corp. (ZOM): $0.50

-0.01 (-2.12%)

POWR Rating

Component Grades














  • ZOM scores best on the Growth dimension, with a Growth rank ahead of 67.27% of US stocks.
  • The strongest trend for ZOM is in Stability, which has been heading down over the past 40 weeks.
  • ZOM ranks lowest in Stability; there it ranks in the 1st percentile.

ZOM Stock Summary

  • With a price/sales ratio of 16,757.6, Zomedica Corp has a higher such ratio than 99.76% of stocks in our set.
  • As for revenue growth, note that ZOM's revenue has grown 111.11% over the past 12 months; that beats the revenue growth of 94.05% of US companies in our set.
  • In terms of volatility of its share price, ZOM is more volatile than 98.7% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Zomedica Corp, a group of peers worth examining would be URG, CVM, TFFP, CALT, and MRSN.
  • Visit ZOM's SEC page to see the company's official filings. To visit the company's web site, go to www.zomedica.com.

ZOM Valuation Summary

  • ZOM's EV/EBIT ratio is -19.6; this is 166.89% lower than that of the median Healthcare stock.
  • ZOM's price/sales ratio has moved NA NA over the prior 46 months.
  • ZOM's price/sales ratio has moved NA NA over the prior 46 months.

Below are key valuation metrics over time for ZOM.

Stock Date P/S P/B P/E EV/EBIT
ZOM 2021-08-31 20836.7 2.3 -34.9 -19.6
ZOM 2021-08-30 20216.7 2.2 -33.9 -18.5
ZOM 2021-08-27 20640.0 2.2 -34.6 -19.2
ZOM 2021-08-26 22533.3 2.4 -37.8 -22.4
ZOM 2021-08-25 18940.0 2.1 -31.7 -16.4
ZOM 2021-08-24 16623.3 1.8 -27.9 -12.5

ZOM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZOM has a Quality Grade of F, ranking ahead of 3.96% of graded US stocks.
  • ZOM's asset turnover comes in at 0 -- ranking 441st of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZOM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 -0.393 -5.936
2021-03-31 0 0.599 -5.609
2020-12-31 0 NA -5.395
2020-09-30 0 NA -6.260
2020-06-30 0 NA -6.329
2020-03-31 0 NA -5.504

ZOM Stock Price Chart Interactive Chart >

Price chart for ZOM

ZOM Price/Volume Stats

Current price $0.50 52-week high $2.91
Prev. close $0.51 52-week low $0.06
Day low $0.50 Volume 22,105,100
Day high $0.51 Avg. volume 77,900,688
50-day MA $0.53 Dividend yield N/A
200-day MA $1.01 Market Cap 488.88M

Zomedica Corp. (ZOM) Company Bio

Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.

ZOM Latest News Stream

Event/Time News Detail
Loading, please wait...

ZOM Latest Social Stream

Loading social stream, please wait...

View Full ZOM Social Stream

Latest ZOM News From Around the Web

Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.

Zomedica Stock Will Need More Than a Change in Management to Bounce Back

While a C-suite scenery change might be good for Zomedica, the shift may not provide a similar outcome for ZOM stock.

Josh Enomoto on InvestorPlace | October 13, 2021

New CEO and Acquisition Could Breathe New Life Into Zomedica

A turnaround in ZOM stock may happen sooner rather than later as Zomedica undergoes an executive-level change and builds out its business.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | October 11, 2021

Zomedica Has Potential, but It’s Far Too Expensive for Now

ZOM stock can be a pet care industry leader, but it needs to make significant improvements before becoming a solid long-term play.

Muslim Farooque on InvestorPlace | October 7, 2021

The Challenges for Zomedica Continue, But It Still Has Huge Potential

Cautious investors may want to hold off, as no matter what direction it goes (higher or lower), it'll do so in a big way.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | October 7, 2021

You Don’t Need a Short Squeeze To Enjoy Lemonade Stock

For exposure to the future of insurance technology -- and a novel, pet-centered preventative care package -- give LMND stock a try.

David Moadel on InvestorPlace | October 5, 2021

Read More 'ZOM' Stories Here

ZOM Price Returns

1-mo -3.10%
3-mo -20.36%
6-mo -46.99%
1-year 553.59%
3-year -69.70%
5-year -52.19%
YTD 116.83%
2020 -30.33%
2019 -73.09%
2018 -37.88%
2017 91.99%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.2132 seconds.